D.E. Shaw & Co’s Novavax NVAX Stock Holding History

D.E. Shaw & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Hold	150,000	–	–	﹤0.01%	3491
2026 Q1	$1.22M	Hold	150,000	–	–	﹤0.01%	3289
2025 Q4	$1.01M	Sell	150,000 -125,000	-45%	-$942K	﹤0.01%	3538
2025 Q3	$2.38M	Hold	275,000	–	–	﹤0.01%	2839
2025 Q2	$1.73M	Buy	+275,000	New	+$1.82M	﹤0.01%	2845
2024 Q1	–	Sell	-60,000	Closed	-$288K	–	4611
2023 Q4	$288K	Sell	60,000 -52,500	-47%	-$321K	﹤0.01%	3760
2023 Q3	$815K	Buy	112,500 +50,000	+80%	+$400K	﹤0.01%	3175
2023 Q2	$464K	Hold	62,500	–	–	﹤0.01%	3450
2023 Q1	$433K	Hold	62,500	–	–	﹤0.01%	3621
2022 Q4	$643K	Sell	62,500 -20,000	-24%	-$353K	﹤0.01%	3715
2022 Q3	$1.5M	Sell	82,500 -29,500	-26%	-$1.28M	﹤0.01%	3255
2022 Q2	$5.76M	Sell	112,000 -251,100	-69%	-$13M	0.01%	1955
2022 Q1	$26.7M	Buy	363,100 +139,700	+63%	+$12.5M	0.03%	841
2021 Q4	$32M	Sell	223,400 -20,000	-8%	-$3.44M	0.03%	789
2021 Q3	$50.5M	Sell	243,400 -49,100	-17%	-$10.8M	0.05%	530
2021 Q2	$62.1M	Buy	292,500 +236,700	+424%	+$43.4M	0.05%	441
2021 Q1	$10.1M	Buy	+55,800	New	+$11.1M	0.01%	1342
2020 Q4	–	Sell	-101,100	Closed	-$11M	–	4094
2020 Q3	$11M	Buy	+101,100	New	+$12.3M	0.01%	1184

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

D.E. Shaw & Co's NVAX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Novavax (NVAX) stake by 27% in Q2 2026, selling an estimated $18.4M and leaving 5,650,905 shares worth $53.2M. The position accounts for 0.03% of the portfolio, ranked #730.

D.E. Shaw & Co first reported a position in NVAX in Q2 2013 and has held it in 48 quarters since. The position peaked at $82.9M in Q2 2020. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

D.E. Shaw & Co held 5,650,905 shares of Novavax worth $53.2M as of Q2 2026.
D.E. Shaw & Co sold 2,058,953 Novavax shares in Q2 2026, an estimated $18.4M.
Novavax made up 0.03% of D.E. Shaw & Co's portfolio in Q2 2026, its #730 holding.
D.E. Shaw & Co first reported a position in Novavax in Q2 2013 and has held it in 48 quarters since.
D.E. Shaw & Co's Novavax position peaked at $82.9M in Q2 2020.
268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.